AlzeCure Pharma AB ("AlzeCure" or the "Company"), a pharmaceutical company developing a broad portfolio of small molecule product candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announces that the Company's Board of Directors today has resolved on a placement of 965 727 shares to Formue Nord Markedsneutral A/S ("Formue Nord"). Formue Nord warranted part of AlzeCure's rights issue (the "Rights Issue") which closed on May 17, 2024 and has expressed a wish to receive its agreed compensation in the form of shares.

The Rights Issue was approved at the Extraordinary General Meeting of AlzeCure on April 25, 2024 and the subscription period expired on May 17, 2024. Formue Nord, which co-guaranteed the Rights Issue, has the right to choose between cash compensation for its commitment or compensation in the form of newly issued shares. To the extent that compensation in the form of shares is chosen, the compensation amounts to twelve percent of the warranted amount, corresponding to SEK 1 641 736, which shall be set off against a subscription price corresponding to the subscription price in the Rights Issue, i.e. SEK 1,70 per share.

Formue Nord has chosen compensation in the form of shares, which is why AlzeCure's Board of Directors today, in accordance with what the warranty agreement stipulates, has decided on a directed new issue to Formue Nord of a maximum of 965 727 shares at a subscription price of SEK 1,70, where the price for newly subscribed shares is set off against the requirement for payment of compensation.

"We are happy and grateful that Formue Nord chooses to receive shares in the company instead of us paying them for their commitment. This improves our liquidity and also shows that they believe in AlzeCure. With the improved liquidity, we can now invest in further activities that benefit the company", says Martin Jönsson, CEO AlzeCure.

Number of shares and share capital
Following registration of the Rights Issue with the Swedish Companies Registration Office, the Company's share capital will increase by SEK 24 143,175 to a total of SEK 2 152 380. The number of shares in the Company will increase by 965 727 shares to a total of 86 095 200 shares.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

Attachments

AlzeCure decides on directed share issue to guarantor

© Modular Finance, source Nordic Press Releases